NATCOPHARM Intraday Analysis...

NATCOPHARM Share Price

Open 770.95 Change Price %
High 817.00 1 Day 34.95 4.51
Low 768.00 1 Week 43.20 5.63
Close 810.25 1 Month 197.95 32.33
Volume 1421217 1 Year 343.00 73.41
52 Week High 817.00
52 Week Low 390.00
NATCOPHARM Important Levels
Resistance 2 855.67
Resistance 1 836.96
Pivot 798.42
Support 1 783.55
Support 2 764.83
NSE INDIA Most Active Stocks
IDEA 119.60 6.22%
JPASSOCIAT 14.75 6.12%
RCOM 36.90 3.22%
JINDALSTEL 116.60 5.76%
SUZLON 18.05 1.69%
BHARTIARTL 366.25 1.45%
ALBK 73.85 4.09%
SOUTHBANK 20.60 0.73%
ICICIBANK 284.50 -0.58%
NHPC 30.15 -0.50%
More..
NSE INDIA Top Gainers Stocks
VKSPL 0.15 50.00%
FARMAXIND 0.15 50.00%
AUSTRAL 0.35 16.67%
GTLINFRA 4.95 16.47%
NICCO 0.40 14.29%
RKDL 12.95 14.10%
ADLABS 87.90 10.50%
GTL 18.60 9.09%
IBWSL 26.25 8.92%
JAMNAAUTO 217.40 8.70%
More..
NSE INDIA Top Losers Stocks
RAJRAYON 0.25 -16.67%
SRGINFOTEC 0.35 -12.50%
MVL 0.45 -10.00%
MVL 0.45 -10.00%
NOESISIND 0.45 -10.00%
ASIL 0.60 -7.69%
REISIXTEN 0.65 -7.14%
SALONA 62.50 -7.06%
UJAAS 35.10 -5.77%
TARMAT 51.05 -5.64%
More..

Natco Pharma Limited (NSE: NATCOPHARM)

NATCOPHARM Technical Analysis 5
As on 23rd Feb 2017 NATCOPHARM Share Price closed @ 810.25 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 583.61 & Strong Buy for SHORT-TERM with Stoploss of 659.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
NATCOPHARM Target for February
1st Target up-side 756.65
2nd Target up-side 802.74
3rd Target up-side 848.83
1st Target down-side 625.15
2nd Target down-side 579.06
3rd Target down-side 532.97
NATCOPHARM Synopsis Technicals View
50 Day EMA N/A (Short Term)
N/A
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
WILLIAM %R (14) N/A N/A
ADX (14) N/A N/A
PSAR N/A N/A
10 Day Avg Volume N/A
NATCOPHARM Other Details
Segment EQ
Market Capital 0.00
Sector Pharmaceuticals
Industry
Offical website
NATCOPHARM Address
NATCOPHARM
N/A
NATCOPHARM Latest News
Natco Pharma - Natco receives Generic Sofosbuvir (Sovaldi) approval for India   Moneycontrol.com   - 12th Mar 15
NATCO Pharma stock rises most on US court ruling   Business Today   - 11th Mar 15
Buy Natco Pharma; target of Rs 1920: ICICIdirect   Moneycontrol.com   - 11th Mar 15
UPDATE 1-India's Natco Pharma ties up with Gilead on hepatitis C drugs   Reuters   - 02nd Mar 15
Natco Pharma - Q3 results on Feb 11, 2015   Moneycontrol.com   - 30th Jan 15
Natco Pharma dips on preferential share allotment at discount   Business Standard   - 17th Dec 14
Natco Pharma CFO passes away   Hindu Business Line   - 23rd Oct 14
Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed. Cir.)   JD Supra (press release)   - 25th Jul 14
Gilead Sciences, Inc. v. Natco Pharma Limited   Lexology (registration)   - 08th May 14
Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed. Cir. 2014)   Patent Docs   - 29th Apr 14
Interactive Technical Analysis Chart Natco Pharma Limited ( NATCOPHARM NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Natco Pharma Limited
NATCOPHARM Business Profile
Natco Pharma is in the Pharmaceuticals sector. The current market capitalisation stands at Rs 2,439.26 crore.The company has reported a consolidated sales of Rs 179.22 crore and a Net Profit of Rs 24.26 crore for the quarter ended Sep 2013.The company management includes V C Nannapaneni - Chairman & Managing Director, Rajeev Nannapaneni - Vice Chairman & CEO, T V Rao - Nominee Director, G S Murthy - Director, B S Bajaj - Director, P Bhaskara Narayana - Director & CFO, A K S Bhujanga Rao - President & Director, Nitin Jagannath Deshmukh - Director. It is listed on the BSE with a BSE Code of 524816 and the NSE with an NSE Code of NATCOPHARM.Its Registered office is at NATCO House, Road No.2,,Banjara Hills Hyderabad,Andhra Pradesh - 500034.Their Registrars are Venture Capital & Corporate Investments Pvt. Ltd.